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This is one of a series of BMJ summaries of new guidelines based on
the best available evidence; they highlight important recommendations
for clinical practice, especially where uncertainty or controversy exists.
Bipolar disorder is a complex, recurrent, and severe mental
illness that has an onset typically between 13 and 30 years of
age and a lifetime prevalence of 1.4%.1 It is characterised by
episodes of mania or hypomania with elation, overactivity, and
disinhibited behaviour, as well as episodes of depression with
profound loss of interest and motivation, often with milder
depressed mood in between episodes. Bipolar disorder is
associated with an increased risk of suicide and physical illness,
such as ischaemic heart disease, diabetes, chronic obstructive
airways disease, pneumonia, and unintentional injury.2 Around
two thirds of people with bipolar disorder also experience
another mental disorder, usually anxiety disorders, substance
misuse disorders, or impulse control disorders.1 The risk of
recurrence in the year after a mood episode is especially high
(50% in one year and >70% at four years) compared with other
psychiatric disorders,3 and this has important implications for
the long term management of the disorder.
This article summarises the most recent recommendations from
the National Institute for Health and Care Excellence (NICE)
on assessing and managing bipolar disorder in adults, children,
and young people.4
Recommendations
NICE recommendations are based on systematic reviews of the
best available evidence and explicit consideration of cost
effectiveness. When minimal evidence is available,
recommendations are based on the Guideline Development
Group’s experience and opinion of what constitutes good
practice. Evidence levels for the recommendations are given in
italic in square brackets.
Care for adults, children, and young people
across all phases of bipolar disorder
• Use this guideline in conjunction with the NICE clinical
guidance on service user experience in adult mental health5
to improve the experience of care by:
-Promoting a positive recovery message from the point of
diagnosis and throughout care
-Building supportive and empathic relationships as an
essential part of care. (New recommendation.) [Based on
the experience and opinion of the Guideline Development
Group (GDG) and on evidence reviewed in one recent
NICE guideline on mental health (CG136)]5
• As early as possible negotiate with the person with bipolar
disorder and his or her carers about how information about
the person will be shared. When discussing rights to
confidentiality, emphasise the importance of sharing
information about risks and the need for carers to
understand the person’s perspective. Foster a collaborative
approach that supports people with bipolar disorder and
their carers and also respects their individual needs and
interdependence. (New recommendation.) [Based on the
experience and opinion of the GDG and on evidence
reviewed in one recent NICE guideline on mental health
(CG178)]6
• When using any psychotropic drugs for bipolar disorder
ensure that:
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-People are given information that is suitable for their
developmental level about the purpose and likely side
effects of treatment, including any monitoring that is
needed, and give them an opportunity to ask questions
-Drugs are chosen in collaboration with the person with
bipolar disorder, taking into account the carer’s views if
the person agrees
-The overall medication regimen is regularly reviewed so
that drugs that are not needed after the acute episode are
stopped. (New recommendation.) [Based on the experience
and opinion of the GDG]
Recognising and managing bipolar disorder
in adults in primary care
• When adults present in primary care with depression, ask
about previous periods of overactivity or disinhibited
behaviour. If the overactivity or disinhibited behaviour has
lasted for four days or more, consider referral for a
specialist mental health assessment. Refer people urgently
for a specialist mental health assessment if mania or severe
depression is suspected (see box for key symptoms or refer
to the ICD-10 (international classification of diseases, 10th
revision) for full diagnostic criteria7) or they are a danger
to themselves or others. (New recommendation.) [Based
on the experience and opinion of the GDG]
• Monitor the physical health of people with bipolar disorder
when responsibility for monitoring is transferred from
secondary care, and then at least annually. The health check
should be comprehensive and focus on physical health
problems, such as cardiovascular disease, diabetes, obesity,
and respiratory disease. A copy of the results should be
sent to the care coordinator and psychiatrist, and it should
be put in the secondary care records. (New
recommendation.) [Based on the experience and opinion
of the GDG and on evidence reviewed in one recent NICE
guideline on mental health (CG178)]6
• Offer people with rapid cycling bipolar disorder the same
interventions as people with other types of bipolar disorder
because there is currently no strong evidence to suggest
that people with rapid cycling bipolar disorder should be
treated differently. (New recommendation.) [Based on the
experience and opinion of the GDG]
Managing mania or hypomania in adults in
secondary care
• If a person develops mania or hypomania and is not taking
an antipsychotic or mood stabiliser, offer haloperidol,
olanzapine, quetiapine, or risperidone, taking into account
any advance statements, the person’s preference, and
clinical context (including physical comorbidity, previous
response to treatment, and side effects). If the person is
already taking lithium, check plasma lithium levels to
optimise treatment and consider adding haloperidol,
olanzapine, quetiapine, or risperidone. Do not offer
lamotrigine to treat mania. (New recommendation.) [Based
on a systematic review and network meta-analysis,8 and
on the experience and opinion of the GDG]
• If a person develops mania or hypomania and is taking an
antidepressant (as defined by the BNF9) as monotherapy:
-Consider stopping the antidepressant and
-Offer an antipsychotic regardless of whether the
antidepressant is stopped. (New recommendation.) [Based
on the experience and opinion of the GDG]
Managing bipolar depression in adults in
secondary care
• Offer adults with bipolar depression:
-A psychological intervention that has been developed
specifically for bipolar disorder and has a published
evidence based manual describing how it should be
delivered or
-A high intensity psychological intervention (cognitive
behavioural therapy, interpersonal therapy, or behavioural
couples therapy) in line with the NICE clinical guideline
on depression.10
Discuss the possible benefits and risks of psychological
interventions and the person’s preference. Monitor mood for
signs of mania or hypomania or deterioration of the depressive
symptoms. (New recommendation.) [Based on a systematic
review and meta-analysis, and on evidence reviewed in one
recent NICE guideline on mental health (CG90)]10
• If a person develops moderate or severe bipolar depression
and is not taking a drug to treat the disorder, offer
fluoxetine combined with olanzapine, or quetiapine on its
own, depending on the person’s preference and previous
response to treatment.
• If the person prefers, consider either olanzapine (without
fluoxetine) or lamotrigine on its own.
• Consider the use of lamotrigine if there is no response to
fluoxetine combined with olanzapine or to quetiapine on
its own. (New recommendation.) [Based on a systematic
review, network meta-analysis, and economic model]
• If a person develops moderate or severe bipolar depression
and is already taking lithium, check the person’s plasma
lithium level. If it is inadequate, increase the dose of
lithium; if it is at maximum level, add either fluoxetine
combined with olanzapine or quetiapine on its own,
depending on the person’s preference and previous response
to treatment.
• If the person prefers, consider adding olanzapine (without
fluoxetine) or lamotrigine to lithium.
• If there is no response to the addition of fluoxetine
combined with olanzapine or quetiapine on its own, stop
the additional treatment and consider adding lamotrigine
to lithium. (New recommendation.) [Based on a systematic
review, network meta-analysis and economic model, and
the experience and opinion of the GDG]
Managing bipolar disorder in adults in the
longer term in secondary care
• After each episode of mania or bipolar depression, discuss
the longer termmanagement of the disorder with the person
and the carers, if appropriate. Discussion should aim to
help people understand that bipolar disorder is often a long
term relapsing and remitting condition that needs self
management and engagement with primary and secondary
care professionals and the involvement of carers. The
discussion should cover:
-The nature and variable course of bipolar disorder
-The role of psychological and pharmacological
interventions to prevent relapse and reduce symptoms
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Decreased need for sleep
Increase in impulsive risk taking behaviour
Depression
Depressed mood
Profound loss of interest in activities
Feelings of worthlessness
Weight loss or gain
Suicidal thoughts or actions
-The risk of relapse after reducing or stopping drugs for
an acute episode
-The potential benefits and risks of long term drugs and
psychological interventions, and the need to monitor mood
and medication
-The potential benefits and risks of stopping drugs,
including for women who may wish to become pregnant
-The person’s history of bipolar disorder, including:
-The severity and frequency of episodes of mania or bipolar
depression, with a focus on associated risks and adverse
consequences
-Previous response to treatment
-Symptoms between episodes
-Potential triggers for relapse, early warning signs, and self
management strategies
-Possible duration of treatment, and when and how often
this should be reviewed.
Provide clear written information about bipolar disorder,
including NICE’s information for the public,11 and ensure there
is enough time to discuss options and concerns. (New
recommendation.) [Based on the experience and opinion of the
GDG]
• Offer a structured psychological intervention (individual,
group, or family), which has been designed for bipolar
disorder and has a published evidence based manual
describing how it should be delivered, to prevent relapse
or for people who have some persisting symptoms between
episodes of mania or bipolar depression. (New
recommendation.) [Based upon very low to moderate
quality randomised evidence and the experience and
opinion of the GDG]
• When planning long term drug treatment to prevent relapse,
take into account drugs that have been effective during
episodes of mania or bipolar depression. Discuss with
people whether they prefer to continue this treatment or
switch to lithium, and explain that lithium is the most
effective long term treatment for bipolar disorder. (New
recommendation.) [Based on the experience and opinion
of the GDG]
• Offer lithium as a first line long term drug treatment for
bipolar disorder and:
-If lithium is ineffective, consider adding valproate
-If lithium is poorly tolerated or is not suitable (for
example, because the person does not agree to routine blood
monitoring), consider valproate or olanzapine instead or,
if it has been effective during an episode of mania or
bipolar depression, quetiapine. (New recommendation.)
[Based on very low to moderate quality randomised
evidence and the experience and opinion of the GDG]
Promoting recovery and return to primary
care
• Offer people with bipolar disorder whose symptoms have
responded effectively to treatment and who remain stable
the option to return to primary care for further management.
If they wish to do this, record it in their notes and
coordinate transfer of responsibilities through the care
programme approach. (New recommendation.) [Based on
the experience and opinion of the GDG]
Recognising and diagnosing bipolar disorder
in children and young people
• If bipolar disorder is suspected in primary care in children
or young people aged under 14 years, refer them to child
and adolescent mental health services (CAMHS). Refer
young people aged 14 years or over to a specialist early
intervention in psychosis service or a CAMHS team with
expertise in the assessment and management of bipolar
disorder in line with the recommendations in this guideline.
(New recommendation.) [Based on the experience and
opinion of the GDG]
• The diagnosis of bipolar disorder should bemade only after
a period of intensive, prospective longitudinal monitoring
by a healthcare professional or multidisciplinary team
trained and experienced in the assessment, diagnosis, and
management of bipolar disorder in children and young
people. This should be done in collaboration with the child
or young person’s parents or carers. (New
recommendation.) [Based on the experience and opinion
of the GDG]
Managing bipolar disorder in children and
young people
• To treat mania or hypomania in young people see NICE’s
technology appraisal guidance on aripiprazole for treating
moderate to severe manic episodes in adolescents with
bipolar I disorder,12 and also consider the recommendations
for adults. In children, refer to the BNF for Children to
modify drug treatments,13 be aware of the increased
potential for a range of side effects, and do not routinely
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continue antipsychotic treatment for longer than 12 weeks.
(New recommendation.) [Based on NICE technology
appraisal 29212 and the experience and opinion of the
GDG]
• Do not offer valproate to girls or young women of
childbearing potential. (New recommendation.) [Based on
the experience and opinion of the GDG]
• Offer a structured psychological intervention (individual
cognitive behavioural therapy or interpersonal therapy) to
young people with bipolar depression. The intervention
should last for at least three months and have a published
evidence based manual that describes how it should be
delivered. (New recommendation.) [Based on the
experience and opinion of the GDG and the content of
other recommendations in the guideline]
Overcoming barriers
There is a perception that because bipolar disorder has important
genetic and biological influences it must be treated with drugs,
and the drug of choice for bipolar depression for many
professionals is an antidepressant.14 This misconception is
challenged by this guideline, which finds that psychological
treatments are effective in the treatment of bipolar depression
in primary and secondary care and in preventing recurrence.
Psychological treatments are also important for young people,
both because young people may benefit from them and because
they are at greater risk of harm with drug treatment.15 However
access to psychological therapies is currently insufficient for
adults and young people with bipolar disorder. For adults, this
guideline also finds that some antipsychotics are effective in
the treatment of bipolar depression, but lithium (rather than
antipsychotics) should be the first line drug to prevent relapse.
A major driver for these changes will be the establishment of
quality networks and national audit. In adults, many mental
health workers have taken the view that smoking, not taking
exercise, and having a poor diet are unimportant compared with
the enormous impact of a bipolar illness.16 These beliefs have
contributed to people with bipolar disorder dying from
preventable diseases much earlier than others.2 This guideline
emphasises the importance of maintaining good physical health
for people with severe mental health problems, such as bipolar
disorder, and we hope it will contribute to a change in
professional attitudes and practice.
There has been much controversy over the diagnosis and
treatment of children and young people with possible bipolar
disorder. In the United States, children as young as 4 or 5 years
are being treated with drugs,17 using criteria for diagnosis that
would not be accepted in the NHS. Thus, increasing numbers
of children and young people are taking antipsychotics,18which
are associated with serious adverse events, including increased
prolactin levels, rapid weight gain, and increased risk of
diabetes.12 The previous NICE guideline rejected the extension
of bipolar disorder into childhood and suggested that clinicians
apply stricter criteria to adolescents,19 but the diagnosis and
treatment of children and adolescents has continued, mostly in
the US.18 This is despite evidence that symptoms are not stable
over time20 and despite limited evidence that young people
benefit from the treatments commonly used in adults.
Importantly, trials in the US show that many children under 13
years diagnosed as having bipolar disorder also have
attention-deficit/hyperactivity disorder,17 21 which might be a
more appropriate diagnosis. The updated guideline reinforces
the findings of the last guideline and finds that extensive use of
this diagnosis in children could cause more harm than good.
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Further information on the guidance
An important prompt for this guideline update was a high quality network meta-analysis of treatments for acute mania published in 2011, in
which haloperidol, olanzapine, quetiapine, and risperidone emerged as the most effective treatments.8 The previous guideline recommended
a range of other alternatives alongside antipsychotics, including valproate and lithium, interventions which were ranked much lower in the
network.
Methods
This guideline, which is an update of NICE clinical guideline 38,19 was developed by the National Collaborating Centre for Mental Health
using NICE guideline methods (www.nice.org.uk/guidelinesmanual). The guideline review process involved comprehensive and systematic
literature searches to identify relevant evidence for the clinical and economic reviews, with critical appraisal of the quality of the identified
evidence. Results of intervention studies were compared using pair-wise and network meta-analyses. Results of the network meta-analysis
were used to inform an economic model. A multidisciplinary team of healthcare professionals from psychiatry, psychology, pharmacology,
occupational therapy, general practice, and nursing, as well as service user and carer representatives (forming the GDG) was established
to review the evidence and develop the subsequent recommendations. The guideline then went through an external consultation with
stakeholders. The GDG considered the stakeholders’ comments, reanalysed the data where necessary, and modified the guideline as
appropriate.
NICE has produced three different versions of the guideline: a full version; a summary version known as the “NICE guideline;” and a version
for children, young people, and adults with bipolar disorder, their parents and carers, and the public.11 All these versions, as well as a pathway,
are available from the NICE website. Further updates of the guideline will be produced as part of NICE’s guideline development programme.
Future research
• What is the clinical and cost effectiveness of structured psychological interventions for young people with bipolar depression?
• In the maintenance treatment of bipolar disorder, what are the relative effects on quality of life of lithium, an antipsychotic (haloperidol,
olanzapine, quetiapine or risperidone), or a combination of lithium and an antipsychotic?
• What is the clinical and cost effectiveness of fluoxetine combined with olanzapine versus an alternative selective serotonin reuptake
inhibitor combined with olanzapine in the treatment of moderate to severe bipolar depression?
• What is the clinical and cost effectiveness of a specialised collaborative care service for people admitted to hospital with bipolar
disorder compared with usual treatment delivered by generic care services?
• What is the clinical and cost effectiveness of face to face cognitive behavioural therapy compared with internet facilitated cognitive
behavioural therapy in the long term management of bipolar disorder?
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